Core Viewpoint - Wanbang Medical (301520.SZ) aims to enhance its competitive edge by leveraging professional institutions and integrating resources through a partnership with Shihezi Longtai Equity Investment Management Partnership [1] Group 1: Investment Details - The company-controlled Hefei Qunxiang Qiming Enterprise Management Partnership (Limited Partnership) will invest 10 million yuan as a limited partner in the Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) [1] - The investment represents a subscription ratio of 12.987% in the partnership [1] Group 2: Investment Focus - The investment will target areas related to new drug research and development, medical device development, and other pharmaceutical sectors [1] - Key focus areas include emerging medical enterprises, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing R&D companies [1]
万邦医药(301520.SZ)：控制的合伙企业拟认购私募基金份额